Research area
Cell & Gene Therapy
Therapeutic cells, gene-based treatments and biological regeneration, including engineered immune cells for cancer.
-
Evidence date ·Could cancer-fighting engineered immune cells help elsewhere?
Peer-Reviewed PaperA 2023 account traces CAR T cells from cancer approval to wider prospects, while patient counts alone cannot show benefit, durability, or safety.
-
Evidence date ·From cancer recognition to a lasting response inside a tumor
Review or Meta-AnalysisA 2022 review explains why engineered immune cells can reach tumors yet lose their target, and why cell-derived vesicles remain experimental.
-
Evidence date ·From breast cancer recognition to a safe CAR-T immune-cell attack
Review or Meta-AnalysisCAR-T cells can recognize breast cancer markers, yet tumor entry, immune suppression, durability, and safety remain separate hurdles in this 2022 review.
-
Evidence date ·What lasting remission could mean after aggressive B-cell lymphoma returns
Review or Meta-AnalysisA May 2022 review explains CAR T-cell therapy for aggressive B-cell lymphoma and why its abstract cannot predict one person’s benefit or risk.
-
Evidence date ·New Zealand’s local cancer cell therapy raises bigger care questions
Clinical TrialA 2021 paper describes local manufacturing for ENABLE and asks how delivery, Māori guardianship and equitable access could shape cancer cell therapy.
-
Evidence date ·Inside a solid tumor, engineered T cells face more than one barrier
Review or Meta-AnalysisA 2021 review explains why engineered T cells face different barriers in solid tumors, from marker recognition and tissue access to local suppression and production.
-
Evidence date ·How adding tumor recognition changes natural killer cells
Review or Meta-AnalysisA 2021 review explains how added receptors guide natural killer cells and why expanding, modifying and preserving them remains difficult.
-
Evidence date ·Several CAR-T medicines share a target while research seeks others
Review or Meta-AnalysisTracked over timeA June 2024 review explains what four approved CAR-T medicines share and what other targets might add, without showing which works best for one patient.
-
Evidence date ·Why cell collection and infusion are separate questions in lymphoma care
Review or Meta-AnalysisTracked over timeA July 2023 review compares earlier CAR T treatment, earlier cell collection, and ready-made antibodies for B-cell lymphoma care.
-
Evidence date ·What do response and remission rates mean when lymphoma returns or resists treatment?
Review or Meta-AnalysisTracked over timeA review of 24 lymphoma trials reports response and remission rates alongside severe reactions. Its abstract does not establish how long responses lasted.